Last reviewed · How we verify
NCT03815747
MRI Evaluation of Change in Gluteal Muscles Following the Treatment With HIFEM Device
NA trial testing High-Intensity Focused Electromagnetic (HIFEM) Field Device in Muscle Tone Increased in 7 participants. Completed in 27 January 2020.
30 July 2019
Quick facts
| Lead sponsor | BTL Industries Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 7 |
| Start date | 11 January 2019 |
| Primary completion | 30 July 2019 |
| Estimated completion | 27 January 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- High-Intensity Focused Electromagnetic (HIFEM) Field Device
Conditions studied
- Muscle Tone Increased — all drugs for Muscle Tone Increased →
Sponsor
BTL Industries Ltd. — full company profile →
Who can join
21 and older, any sex, with Muscle Tone Increased. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will use magnetic resonance imaging (MRI) to evaluate changes in gluteal muscle following the treatment with HIFEM stimulation for aesthetic improvement of buttocks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03815747
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of High-Intensity Focused Electromagnetic (HIFEM) Field Device
Trials testing the same drug.
- NCT03758690 — High-Intensity Focused Electromagnetic (HIFEM) Field Device in Women After Childbirth · NA · completed
Other recruiting trials for Muscle Tone Increased
Currently open trials in the same condition.
- NCT05256771 — Electrical Muscle Stimulation with 1064 Nm Diode Laser and RF/PEMF for Non-invasive Body Contouring and Fat Reduction. · NA · active not recruiting
Other BTL Industries Ltd. trials
Trials by the same sponsor.
- NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E · NA · recruiting
- NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting
- NCT07179224 — EEG Changes After rTMS Stimulation · NA · completed
- NCT07024550 — Impact of the EXOMIND (BTL-699-2) on the Brain Reward Pathway · NA · active not recruiting
- NCT07027657 — EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03815747 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BTL Industries Ltd.
- Last refreshed: 20 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03815747.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing